T-cell-mediated cytotoxicity may play an important role in control of infection by the human immunodeficiency virus (HIV). In this study, we have identified and characterized a relatively conserved epitope in the HIV-1 reverse transcriptase recognized by murine and human cytotoxic T cells. This epitope was identified using a murine antigen-specific CD8+ class I major histocompatibility complex-restricted cytotoxic T-cell (CTL) line, a transfected fibroblast cell line expressing the HIV-1 pol gene, recombinant vaccinia viruses containing different truncated versions of the pol gene, and overlapping synthetic peptides. The optimal antigenic site was identified as residues 203-219 by synthesizing extended or truncated peptide analogs of the antigenic fragment. The optimal peptide was then tested for sensitization of autologous Epstein-Barr virus-transformed B-cell targets for killing by fresh human peripheral blood mononuclear cells.
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It was recognized by CTLs from several HIV-seropositive patients but not from any seronegative donor. Therefore, this peptide is a good candidate for inclusion in an AIDS vaccine. This study demonstrates that the same CTL epitope can be seen by murine and human CD8' CTLs, as previously demonstrated for epitopes recognized by CD4+ helper T cells, and suggests the utility of screening for immunodominant CTL epitopes in mice prior to carrying out studies in humans.
Cytotoxic T lymphocytes (CTLs) have been found to mediate protection in vivo against certain virus-induced diseases, including some caused by retroviruses (1) (2) (3) . This defense mechanism might be particularly relevant against the human immunodeficiency virus (HIV), which can spread through cell-cell contact and thus may not be accessible to antibody neutralization. Indeed, CD8+ cells have been shown to inhibit growth of HIV or simian immunodeficiency virus in cells of infected patients or monkeys (4, 5) . Efforts have thus been directed at studying the CTL response against different proteins of HIV. Human CD3+ 8+ CTLs specific for the envelope glycoprotein gpl60 have been identified (6) (7) (8) (9) (10) (11) (12) , and an immunodominant CTL epitope has been mapped in H-2d mice to residues 315-329, a highly variable region of the envelope (13) . However, immunizing with the whole envelope protein is not an ideal approach for several reasons. (i) The majority of the cytotoxic response assayed in vitro with fresh peripheral blood mononuclear cells (PBMCs) from HIV-seropositive individuals seems to be mediated by non (20) . Anti-gp120 antibodies can also inhibit CD4' T-cell function like anti-CD4 antibodies by binding to gpl20, which binds to CD4 (21) . Also, gpl60 can elicit autoantibodies that crossreact with human class II MHC molecules and inhibit T-cell function (22) . Finally, gpl20 itself may inhibit T-cell function directly (19) .
In contrast to the envelope glycoprotein, the internal proteins of HIV are more conserved and would be less likely to contribute to these deleterious effects. Moreover, in other viral models, internal proteins are the predominant targets of the CTL response (23) (24) (25) (26) (27) (28) . Responses have been found in HIV patients against the products of the gag, pol, nef, and vif genes (7, 9, 12, 29, 30) . Because of its conservation and importance to viral function, the reverse transcriptase (RT) appears to be worth particular interest in this regard. We describe here our approach of using a murine model to identify evolutionarily conserved CTL determinants in RT and the relevance of this identification to human anti-HIV cytotoxic responses.
MATERIALS AND METHODS
Mice. C3H/HeJ (H-2k) mice were obtained from The Jackson Laboratory.
Recombinant Vaccinia Viruses. v-pol (vCF-21, Fig. 1 (1990) 2345 in this paper v-pol-100, -80, -67, -58, and -27, respectively, to indicate the proportional length of their inserts as a percentage of the v-pol-100 insert length (Fig. 1) . These inserts all initiate at the 5' end of the original insert, corresponding to residue 168 of the amino acid sequence and to the N-terminal end of the processed protein. The negative control recombinant vaccinia virus v-ctrl (vSC-8) (34) contains the Escherichia coli lacZ gene as a control.
Transfectants. The transfectant L-pol was prepared using the pcEXV-3 vector containing the same RT-encoding insert as v-pol. pcEXV-3-pol was cotransfected with pSV2neo into DAP3 L cells using the CaPO4 method (35) (32) that was expressed by the virus v-pol-27 was synthesized and purified as described (13, 36) . Their molar concentration was determined by HPLC or by spectrophotometry. A series of analogs of peptide HP138 has been synthesized on an ABI automated synthesizer, cleaved by low HF procedure, desalted either by Bio-Gel PA or by reverse-phase (C18 Sep-Pak, Waters) chromatography, and purified to a single HPLC peak (C18 column, Waters). Amino acid analysis (performed by 0. Bates and colleagues, University of California, Irvine) confirmed the expected sequences.
Patient Source and Clinical Evaluation. HIV+ patients were obtained from Wilford Hall, U.S. Air Force Medical Center, Lackland Air Force Base. Individuals were diagnosed as being HIV infected ifanti-HIV antibodies were demonstrated on two specimens tested by the HIV enzyme immunoassay (Abbott) and confirmed by Western blot analysis (Roche Biomedical Laboratories, Burlington, NC). Patients were classified according to the Walter Reed staging system (37).
Lymphocyte counts and T-cell subsets were determined using laser-based flow cytometry (Coulter epics profile) and OKT4A (anti-CD4) and OKT8 (anti-CD8) monoclonal antibodies (Ortho Diagnostics). (Fig. 1) was responsible for targeting the cytotoxic activity, HP138 was tested individually and was found to sensitize targets (Fig. 2) . However, none of the other peptides was able to sensitize targets (Fig. 2) , including HP137 and HP139 (that overlap HP138 by nine and five residues, respectively), even when tested individually (data not shown). HP138 (CysThr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro) corresponds to residues 205-219 of the HTLV-III/B strain sequence (32) . It is not toxic by itself as determined by spontaneous lysis and cell recovery in the presence ofpeptide alone (data not shown). The line Pol a was class I MHCrestricted because it killed HP138-pulsed, class II MHC molecule-negative H-2k L-cell fibroblasts but not 3T3 fibroblasts (H-2d) or EL4 thymoma cells (H-2b). It was demonstrated to be CD4-, CD8' by treatment with anti-CD8 or anti-CD4 monoclonal antibodies and complement (data not shown).
RESULTS
Definition of the Optimal Epitope. Because HP138 sensitized targets best at high concentrations (20 jLM), we synthesized and purified a series of peptide analogs in the area of HP138 to determine whether activity could be improved by extending or shortening the peptide by a few residues. The addition of two amino acids (Fig. 3) the elongation on the C terminus that enhanced the activity in 205-223, but surprisingly its activity was not better than that of 205-223 ( (Fig. 4 Upper). The PBMCs from both patients were able to kill specifically targets preincubated with these two peptides but not targets preincubated with a control peptide or with medium only. Conversely, the PBMCs from both seronegative donors failed to kill the targets incubated with either peptide but did show some killing on autologous target cells infected with the control vaccinia virus (Fig. 4 Lower), as several other investigators have found in similar studies (6, 7, 9, 30) . The significance ofthis response is not clear, because the vaccinia virus immunization history of the patients and the controls shown in Fig. 4 was not available to us. The two patients, but not the healthy controls, also showed a high cytotoxic activity against the targets infected with the pol-recombinant vaccinia virus (Fig. 4 (38) to be able to fold as an amphipathic 310 helix, consistent with previously observed properties of T-cell epitopes (38) .
Many class II-restricted T-cell epitopes have been identified, but in most cases they have not been studied in more than one species. We have identified several epitopes from HIV and malaria proteins seen by class II MHC-restricted proliferative T cells in mice, and every one of these tested with T cells from immune humans stimulated the human T cells as well (44) (45) (46) (47) (48) (49) . A similar case has been found for influenza (50, 51 The most useful epitopes for a vaccine should be immunodominant-i.e., recognized by a majority of T-cell clones in a bulk cell population. However, it is difficult to obtain sufficient quantities of blood from HIV-infected patients to screen large numbers of peptides on whole peripheral blood cell populations. Infected blood donors are usually unavailable for repeated blood drawing, and to allow time for production of EBV-transformed target cell lines, one must use as effectors cryopreserved cells with recoveries often of only 50%. In our experience, no more than 10-12 peptides, including controls, can be tested from a single bleed. Therefore, our approach, with class II as well as with class I MHC-restricted epitopes, has been to locate and characterize them first in mice and then to test them with human cells. The T-cell receptor and MHC molecule structures are very conserved between mice and humans (53, 54 
